Nishikori Momoko

Affiliation and department：

Research field (1)： Hematology and oncology

Research theme for competitive and other funds (7)：

2021 - 2024 新規エピゲノム修飾薬のB細胞リンパ腫に対する奏効予測モデルの確立とその治療応用
2018 - 2021 Clarifying the significance of Notch signal activation in B-cell lymphomas
2015 - 2018 Clarifying the pathogenesis of ABC-DLBCL in a mouse model
2012 - 2015 Analysis of clonal hierarchy and microenvironment of the tumor developed in the mouse mantle cell lymphoma model
2008 - 2009 In vivo characterization of B cells with lymphoma-specific translocat in mice and their potential roles in lymphoma development.

Show all

Papers (94)：

Naokazu Nakamura, Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo. Clinical impact of CRS on prolonged hematotoxicity after CAR-T cell therapy: KyoTox a-score, a novel prediction model. Transplantation and cellular therapy. 2024
Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Naokazu Nakamura, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo. KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis. Bone Marrow Transplantation. 2023
Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo. Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy. Scientific Reports. 2023. 13. 1
Fumiya Wada, Yasuyuki Arai, Tomoyasu Jo, Chisaki Mizumoto, Junya Kanda, Toshio Kitawaki, Momoko Nishikori, Kouhei Yamashita, Akifumi Takaori-Kondo. Impact of Antimicrobial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 2023
Kensuke Nakao, Momoko Nishikori, Masakazu Fujimoto, Hiroshi Arima, Hironori Haga, Akifumi Takaori-Kondo. Concurrent development of small lymphocytic lymphoma and lung cancer: A report of two cases and a review of the literature. Journal of clinical and experimental hematopathology : JCEH. 2023. 63. 2. 132-138

ｍore...

MISC (89)：

田嶋哲也, 田嶋哲也, 秦浩一郎, 秦浩一郎, 日下部治郎, 日下部治郎, 宮内英孝, 宮内英孝, 万木紀美子, 菱田理恵, et al. 血液型不適合/既存ドナー特異的抗体陽性肝移植における抗体関連拒絶反応の発症危険因子は何か?. 日本移植学会総会プログラム抄録集. 2021. 57th (Web)
田嶋哲也, 秦浩一郎, 羽賀博典, 錦織桃子, 日下部治郎, 宮内英孝, 岡本竜弥, 小川絵里, 園田真理, 岡島英明, et al. 肝移植後リンパ増殖性疾患(PTLD)の頻度,治療とその予後~当院1,954例の後方視的解析から~. 日本外科学会定期学術集会(Web). 2021. 121st
牧野恭秀, 荒川芳輝, 丹治正大, 峰晴陽平, 錦織桃子, 高折晃史, 宇藤恵, 溝脇尚志, 宮本享. The current situation and problem of treatment for primary central nervous system lymphoma in elders. 日本脳腫瘍学会プログラム・抄録集. 2020. 38th
田嶋哲也, 秦浩一郎, 日下部治郎, 宮内英孝, 穴澤貴之, 錦織桃子, 海道利実, 羽賀博典, 高折晃史, 上本伸二. 血液型不適合肝臓移植の現状と課題 Rituximabによる術前減感作療法時代の血液型不適合成人生体肝移植の治療成績抗体関連拒絶反応発症の危険因子は何か?. 移植. 2019. 54. 総会臨時. 186-186
宮崎香奈, 浅野直子, 山田知美, 宮脇恒太, 高崎啓孝, 五十嵐忠彦, 錦織桃子, 大畑欣也, 角南一貴, 吉田功, et al. CD5+ DLBCLに対するDA-EPOCH-R/大量MTX療法 PEARL5試験の主解析結果(DA-EPOCH-R with high-dose methotrexate(HD-MTX) for CD5+ DLBCL: Primary analysis of PEARL5 study). 臨床血液. 2018. 59. 9. 1556-1556

ｍore...

Lectures and oral presentations (48)：

濾胞性リンパ腫の病態と治療
(第127回日本血液学会東北地方会 2019)
Recent advances in the treatment of Hodgkin lymphoma.
(2018)
悪性リンパ腫の治療の新たな方向性
(第109回近畿血液学地方会 2018)
悪性リンパ腫の発症機序を考える
(日本血液学会学術集会 2016)
B細胞リンパ腫
(第8回研修医のための血液学セミナーランチョンセミナー 2016)

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page